Cargando…
P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429782/ http://dx.doi.org/10.1097/01.HS9.0000968928.84153.89 |
| _version_ | 1785090798081015808 |
|---|---|
| author | Venditti, Adriano Piciocchi, Alfonso Maurillo, Luca Ilaria Del Principe, Maria Palmieri, Raffaele Soddu, Stefano Moretti, Federico Salutari, Prassede Martelli, Maurizio Paola Martelli, Maria Luppi, Mario Pulsoni, Alessandro Zaja, Francesco Cairoli, Roberto Pane, Fabrizio Siragusa, Sergio Bassan, Renato Rondoni, Michela Mirabile, Milena Mulè, Antonino Beltrami, Germana Zappasodi, Patrizia Cudillo, Laura Mengarelli, Andrea Curti, Antonio Ferrara, Felicetto Rossi, Giovanni Audisio, Ernesta Spinosa, Giuseppina Tieghi, Alessia Bocchia, Monica Martini, Vincenza Califano, Catello Rigacci, Luigi Tafuri, Agostino Gottardi, Michele Fazi, Paola Vignetti, Marco Buccisano, Francesco |
| author_facet | Venditti, Adriano Piciocchi, Alfonso Maurillo, Luca Ilaria Del Principe, Maria Palmieri, Raffaele Soddu, Stefano Moretti, Federico Salutari, Prassede Martelli, Maurizio Paola Martelli, Maria Luppi, Mario Pulsoni, Alessandro Zaja, Francesco Cairoli, Roberto Pane, Fabrizio Siragusa, Sergio Bassan, Renato Rondoni, Michela Mirabile, Milena Mulè, Antonino Beltrami, Germana Zappasodi, Patrizia Cudillo, Laura Mengarelli, Andrea Curti, Antonio Ferrara, Felicetto Rossi, Giovanni Audisio, Ernesta Spinosa, Giuseppina Tieghi, Alessia Bocchia, Monica Martini, Vincenza Califano, Catello Rigacci, Luigi Tafuri, Agostino Gottardi, Michele Fazi, Paola Vignetti, Marco Buccisano, Francesco |
| author_sort | Venditti, Adriano |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429782 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104297822023-08-17 P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA Venditti, Adriano Piciocchi, Alfonso Maurillo, Luca Ilaria Del Principe, Maria Palmieri, Raffaele Soddu, Stefano Moretti, Federico Salutari, Prassede Martelli, Maurizio Paola Martelli, Maria Luppi, Mario Pulsoni, Alessandro Zaja, Francesco Cairoli, Roberto Pane, Fabrizio Siragusa, Sergio Bassan, Renato Rondoni, Michela Mirabile, Milena Mulè, Antonino Beltrami, Germana Zappasodi, Patrizia Cudillo, Laura Mengarelli, Andrea Curti, Antonio Ferrara, Felicetto Rossi, Giovanni Audisio, Ernesta Spinosa, Giuseppina Tieghi, Alessia Bocchia, Monica Martini, Vincenza Califano, Catello Rigacci, Luigi Tafuri, Agostino Gottardi, Michele Fazi, Paola Vignetti, Marco Buccisano, Francesco Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429782/ http://dx.doi.org/10.1097/01.HS9.0000968928.84153.89 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Venditti, Adriano Piciocchi, Alfonso Maurillo, Luca Ilaria Del Principe, Maria Palmieri, Raffaele Soddu, Stefano Moretti, Federico Salutari, Prassede Martelli, Maurizio Paola Martelli, Maria Luppi, Mario Pulsoni, Alessandro Zaja, Francesco Cairoli, Roberto Pane, Fabrizio Siragusa, Sergio Bassan, Renato Rondoni, Michela Mirabile, Milena Mulè, Antonino Beltrami, Germana Zappasodi, Patrizia Cudillo, Laura Mengarelli, Andrea Curti, Antonio Ferrara, Felicetto Rossi, Giovanni Audisio, Ernesta Spinosa, Giuseppina Tieghi, Alessia Bocchia, Monica Martini, Vincenza Califano, Catello Rigacci, Luigi Tafuri, Agostino Gottardi, Michele Fazi, Paola Vignetti, Marco Buccisano, Francesco P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA |
| title | P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA |
| title_full | P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA |
| title_fullStr | P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA |
| title_full_unstemmed | P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA |
| title_short | P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA |
| title_sort | p505: gimema aml1819 trial: gemtuzumab ozogamicin plus intensive chemotherapy impacts on the level of post-consolidation measurable residual disease (mrd) in acute myeloid leukemia |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429782/ http://dx.doi.org/10.1097/01.HS9.0000968928.84153.89 |
| work_keys_str_mv | AT vendittiadriano p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT piciocchialfonso p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT maurilloluca p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT ilariadelprincipemaria p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT palmieriraffaele p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT soddustefano p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT morettifederico p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT salutariprassede p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT martellimaurizio p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT paolamartellimaria p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT luppimario p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT pulsonialessandro p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT zajafrancesco p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT cairoliroberto p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT panefabrizio p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT siragusasergio p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT bassanrenato p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT rondonimichela p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT mirabilemilena p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT muleantonino p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT beltramigermana p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT zappasodipatrizia p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT cudillolaura p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT mengarelliandrea p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT curtiantonio p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT ferrarafelicetto p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT rossigiovanni p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT audisioernesta p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT spinosagiuseppina p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT tieghialessia p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT bocchiamonica p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT martinivincenza p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT califanocatello p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT rigacciluigi p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT tafuriagostino p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT gottardimichele p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT fazipaola p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT vignettimarco p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia AT buccisanofrancesco p505gimemaaml1819trialgemtuzumabozogamicinplusintensivechemotherapyimpactsonthelevelofpostconsolidationmeasurableresidualdiseasemrdinacutemyeloidleukemia |